{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:11:51Z","timestamp":1793391111745,"version":"4.5.0"},"reference-count":94,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T00:00:00Z","timestamp":1593648000000},"content-version":"vor","delay-in-days":367,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","imaging.onlinejacc.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Cardiovascular Imaging"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.jcmg.2018.11.039","type":"journal-article","created":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T19:19:04Z","timestamp":1562008744000},"page":"1230-1242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":111,"special_numbering":"P1","title":["The Role of Cardiac Imaging in the Diagnosis and Management of Anderson-Fabry Disease"],"prefix":"10.1016","volume":"12","author":[{"given":"Rebecca","family":"Perry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madiha","family":"Saiedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjana","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Ganesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ales","family":"Linhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph B.","family":"Selvanayagam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcmg.2018.11.039_bib1","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0735-1097(02)02380-X","article-title":"Cardiac manifestations of Anderson-Fabry disease in heterozygous females","volume":"40","author":"Kampmann","year":"2002","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcmg.2018.11.039_bib2","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/01.CIR.0000139847.74101.03","article-title":"Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy","volume":"110","author":"Chimenti","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jcmg.2018.11.039_bib3","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1161\/01.CIR.0000091253.71282.04","article-title":"Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study","volume":"108","author":"Weidemann","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jcmg.2018.11.039_bib4","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1067\/mhj.2000.105105","article-title":"New insights in cardiac structural changes in patients with Fabry's disease","volume":"139","author":"Linhart","year":"2000","journal-title":"Am Heart J"},{"key":"10.1016\/j.jcmg.2018.11.039_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcmg.2018.11.039_bib6","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry's disease with the pharmacologic chaperone migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcmg.2018.11.039_bib7","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18\u2013month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.jcmg.2018.11.039_bib8","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","article-title":"Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document","volume":"10","author":"Biegstraaten","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jcmg.2018.11.039_bib9","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jcmg.2018.11.039_bib10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pharmthera.2009.01.003","article-title":"Fabry disease","volume":"122","author":"Schiffmann","year":"2009","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jcmg.2018.11.039_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jmedgenet-2013-101857","article-title":"A\u00a0systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance","volume":"51","author":"van der Tol","year":"2014","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.jcmg.2018.11.039_bib12","doi-asserted-by":"crossref","unstructured":"Linhart A, Kampmann C, Zamorano JL, et\u00a0al. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 2007;28:1228\u201335.","DOI":"10.1093\/eurheartj\/ehm153"},{"key":"10.1016\/j.jcmg.2018.11.039_bib13","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","article-title":"Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry registry","volume":"11","author":"Waldek","year":"2009","journal-title":"Genet Med"},{"key":"10.1016\/j.jcmg.2018.11.039_bib14","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.hrthm.2014.03.043","article-title":"HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis","volume":"11","author":"Birnie","year":"2014","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jcmg.2018.11.039_bib15","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/j.jacc.2016.07.741","article-title":"Cardiac Fabry disease with late gadolinium enhancement is a chronic inflammatory cardiomyopathy","volume":"68","author":"Nordin","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcmg.2018.11.039_bib16","article-title":"Proposed stages of myocardial phenotype development in Fabry disease","author":"Nordin","year":"2018","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jcmg.2018.11.039_bib17","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","article-title":"Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey","volume":"28","author":"Linhart","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcmg.2018.11.039_bib18","doi-asserted-by":"crossref","first-page":"f153","DOI":"10.1093\/europace\/eux261","article-title":"Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in clinical practice","volume":"20","author":"Baig","year":"2018","journal-title":"Europace"},{"key":"10.1016\/j.jcmg.2018.11.039_bib19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/08035320510028049","article-title":"The right ventricle in Fabry disease","volume":"94","author":"Kampmann","year":"2005","journal-title":"Acta Paediatr Suppl"},{"key":"10.1016\/j.jcmg.2018.11.039_bib20","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1136\/hrt.2010.204586","article-title":"The right ventricle in Fabry disease: natural history and impact of enzyme replacement therapy","volume":"96","author":"Niemann","year":"2010","journal-title":"Heart"},{"key":"10.1016\/j.jcmg.2018.11.039_bib21","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.echo.2013.08.024","article-title":"Left atrial enlargement and reduced atrial compliance occurs early in Fabry cardiomyopathy","volume":"26","author":"Boyd","year":"2013","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.jcmg.2018.11.039_bib22","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.jacc.2005.11.070","article-title":"Fabry's disease cardiomyopathy: echocardiographic detection of endomyocardial glycosphingolipid compartmentalization","volume":"47","author":"Pieroni","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcmg.2018.11.039_bib23","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.jacc.2008.02.046","article-title":"The binary endocardial appearance is a poor discriminator of Anderson-Fabry disease from familial hypertrophic cardiomyopathy","volume":"51","author":"Kounas","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcmg.2018.11.039_bib24","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/ejechocard\/jer112","article-title":"The endocardial binary appearance ('binary sign') is an unreliable marker for echocardiographic detection of Fabry disease in patients with left ventricular hypertrophy","volume":"12","author":"Mundigler","year":"2011","journal-title":"Eur J Echocardiogr"},{"key":"10.1016\/j.jcmg.2018.11.039_bib25","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1161\/01.CIR.104.2.128","article-title":"Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy","volume":"104","author":"Nagueh","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jcmg.2018.11.039_bib26","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.euje.2004.09.010","article-title":"The use of tissue Doppler imaging for the assessment of changes in myocardial structure and function in inherited cardiomyopathies","volume":"6","author":"De Backer","year":"2005","journal-title":"Eur J Echocardiogr"},{"key":"10.1016\/j.jcmg.2018.11.039_bib27","doi-asserted-by":"crossref","unstructured":"Pieroni M, Chimenti C, Ricci R, Sale P, Russo MA, Frustaci A. Early detection of Fabry cardiomyopathy by tissue Doppler imaging. Circulation 2003;107:1978\u201384.","DOI":"10.1161\/01.CIR.0000061952.27445.A0"},{"key":"10.1016\/j.jcmg.2018.11.039_bib28","doi-asserted-by":"crossref","unstructured":"Weidemann F, Niemann M, Stork S, et\u00a0al. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med 2013;274:331\u201341.","DOI":"10.1111\/joim.12077"},{"key":"10.1016\/j.jcmg.2018.11.039_bib29","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/ejechocard\/jer109","article-title":"Usefulness of tissue Doppler on early detection of cardiac disease in Fabry patients and potential role of enzyme replacement therapy (ERT) for avoiding progression of disease","volume":"12","author":"Zamorano","year":"2011","journal-title":"Eur J Echocardiogr"},{"key":"10.1016\/j.jcmg.2018.11.039_bib30","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.echo.2013.09.005","article-title":"Systolic and diastolic function assessment in fabry disease patients using speckle-tracking imaging and comparison with conventional echocardiographic measurements","volume":"26","author":"Shanks","year":"2013","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.jcmg.2018.11.039_bib31","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1093\/eurheartj\/eht098","article-title":"Two-dimensional speckle tracking as a non-invasive tool for identification of myocardial fibrosis in Fabry disease","volume":"34","author":"Kramer","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcmg.2018.11.039_bib32","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/echo.12216","article-title":"Two-dimensional speckle tracking echocardiography for early detection of myocardial damage in young patients with Fabry disease","volume":"30","author":"Saccheri","year":"2013","journal-title":"Echocardiography"},{"key":"10.1016\/j.jcmg.2018.11.039_bib33","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/echo.13496","article-title":"Loss of base-to-apex circumferential strain gradient: a specific pattern of Fabry cardiomyopathy?","volume":"34","author":"Labombarda","year":"2017","journal-title":"Echocardiography"},{"key":"10.1016\/j.jcmg.2018.11.039_bib34","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10554-014-0551-4","article-title":"Global cardiac alterations detected by speckle-tracking echocardiography in Fabry disease: left ventricular, right ventricular, and left atrial dysfunction are common and linked to worse symptomatic status","volume":"31","author":"Morris","year":"2015","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2018.11.039_bib35","doi-asserted-by":"crossref","DOI":"10.1111\/echo.13829","article-title":"Comparison of left atrial size and function in hypertrophic cardiomyopathy and in Fabry disease with left ventricular hypertrophy","author":"Saccheri","year":"2018","journal-title":"Echocardiography"},{"key":"10.1016\/j.jcmg.2018.11.039_bib36","doi-asserted-by":"crossref","unstructured":"Pichette M, Serri K, Page M, Di LZ, Bichet DG, Poulin F. Impaired left atrial function in Fabry Disease: a longitudinal speckle-tracking echocardiography study. J Am Soc Echocardiogr 2017;30:170\u2013179.","DOI":"10.1016\/j.echo.2016.10.014"},{"key":"10.1016\/j.jcmg.2018.11.039_bib37","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/heartjnl-2015-308494","article-title":"Cardiac involvement in genotype-positive Fabry disease patients assessed by cardiovascular MR","volume":"102","author":"Kozor","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.jcmg.2018.11.039_bib38","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12968-015-0114-4","article-title":"A\u00a0disproportionate contribution of papillary muscles and trabeculations to total left ventricular mass makes choice of cardiovascular magnetic resonance analysis technique critical in Fabry disease","volume":"17","author":"Kozor","year":"2015","journal-title":"J\u00a0Cardiovasc Magn Reson"},{"key":"10.1016\/j.jcmg.2018.11.039_bib39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ultrasmedbio.2010.10.017","article-title":"Prominent papillary muscles in Fabry disease: a diagnostic marker?","volume":"37","author":"Niemann","year":"2011","journal-title":"Ultrasound Med Biol"},{"key":"10.1016\/j.jcmg.2018.11.039_bib40","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/00004728-200605000-00013","article-title":"Left ventricular papillary muscle mass: relationship to left ventricular mass and volumes by magnetic resonance imaging","volume":"30","author":"Vogel-Claussen","year":"2006","journal-title":"J\u00a0Comput Assist Tomogr"},{"key":"10.1016\/j.jcmg.2018.11.039_bib41","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1148\/radiol.2353040601","article-title":"Effect of endocardial trabeculae on left ventricular measurements and measurement reproducibility at cardiovascular MR imaging","volume":"236","author":"Papavassiliu","year":"2005","journal-title":"Radiology"},{"key":"10.1016\/j.jcmg.2018.11.039_bib42","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.jcmg.2012.05.015","article-title":"Correlation of trabeculae and papillary muscles with clinical and cardiac characteristics and impact on CMR measures of LV anatomy and function","volume":"5","author":"Chuang","year":"2012","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jcmg.2018.11.039_bib43","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.ehj.2003.09.017","article-title":"Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium","volume":"24","author":"Moon","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcmg.2018.11.039_bib44","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12968-016-0233-6","article-title":"Cardiovascular magnetic resonance demonstration of the spectrum of morphological phenotypes and patterns of myocardial scarring in Anderson-Fabry disease","volume":"18","author":"Deva","year":"2016","journal-title":"J\u00a0Cardiovasc Magn Reson"},{"key":"10.1016\/j.jcmg.2018.11.039_bib45","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jcmg.2011.01.020","article-title":"Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment","volume":"4","author":"Niemann","year":"2011","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jcmg.2018.11.039_bib46","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1161\/CIRCIMAGING.112.000070","article-title":"Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping","volume":"6","author":"Sado","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2018.11.039_bib47","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12968-014-0099-4","article-title":"Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance","volume":"16","author":"Pica","year":"2014","journal-title":"J\u00a0Cardiovasc Magn Reson"},{"key":"10.1016\/j.jcmg.2018.11.039_bib48","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.echo.2008.09.002","article-title":"Right ventricular involvement in Fabry disease","volume":"21","author":"Palecek","year":"2008","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.jcmg.2018.11.039_bib49","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.echo.2010.05.020","article-title":"The different faces of echocardiographic left ventricular hypertrophy: clues to the etiology","volume":"23","author":"Weidemann","year":"2010","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.jcmg.2018.11.039_bib50","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/eurheartj\/ehi143","article-title":"The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease","volume":"26","author":"Weidemann","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcmg.2018.11.039_bib51","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ijcard.2007.01.089","article-title":"Patterns of left ventricular hypertrophy in essential hypertension: should echocardiography guide the pharmacological treatment?","volume":"124","author":"Davila","year":"2008","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jcmg.2018.11.039_bib52","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1161\/01.CIR.63.1.188","article-title":"M-mode and two-dimensional echocardiographic features in cardiac amyloidosis","volume":"63","author":"Siqueira-Filho","year":"1981","journal-title":"Circulation"},{"key":"10.1016\/j.jcmg.2018.11.039_bib53","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1476-7120-8-7","article-title":"Echocardiography in patients with hypertrophic cardiomyopathy: usefulness of old and new techniques in the diagnosis and pathophysiological assessment","volume":"8","author":"Losi","year":"2010","journal-title":"Cardiovasc Ultrasound"},{"key":"10.1016\/j.jcmg.2018.11.039_bib54","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/0735-1097(95)00390-8","article-title":"Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two\u2013dimensional echocardiography in 600 patients","volume":"26","author":"Klues","year":"1995","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcmg.2018.11.039_bib55","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1161\/CIRCIMAGING.113.000683","article-title":"Effect of combined systolic and diastolic functional parameter assessment for differentiation of cardiac amyloidosis from other causes of concentric left ventricular hypertrophy","volume":"6","author":"Liu","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2018.11.039_bib56","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/echo.12079","article-title":"Two- and three-dimensional speckle tracking echocardiography: clinical applications and future directions","volume":"30","author":"Biswas","year":"2013","journal-title":"Echocardiography"},{"key":"10.1016\/j.jcmg.2018.11.039_bib57","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.echo.2008.10.006","article-title":"Progression of left ventricular functional abnormalities in hypertensive patients with heart failure: an ultrasonic two-dimensional speckle tracking study","volume":"21","author":"Kosmala","year":"2008","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.jcmg.2018.11.039_bib58","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jash.2015.11.006","article-title":"The septal bulge: an early echocardiographic sign in hypertensive heart disease","volume":"10","author":"Gaudron","year":"2016","journal-title":"J\u00a0Am Soc Hypertens"},{"key":"10.1016\/j.jcmg.2018.11.039_bib59","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/eurheartj\/ehr084","article-title":"Alterations in multidirectional myocardial functions in patients with aortic stenosis and preserved ejection fraction: a two-dimensional speckle tracking analysis","volume":"32","author":"Ng","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcmg.2018.11.039_bib60","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","article-title":"Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis","volume":"98","author":"Phelan","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.jcmg.2018.11.039_bib61","article-title":"Impact of regional left ventricular function on outcome for patients with AL amyloidosis","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jcmg.2018.11.039_bib62","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.117.007168","article-title":"Cardiac phenotype of prehypertrophic Fabry disease","volume":"11","author":"Nordin","year":"2018","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2018.11.039_bib63","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jcmg.2018.11.039_bib64","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.jpeds.2009.07.003","article-title":"Guidelines to diagnosis and monitoring of Fabry disease and review of treatment experiences","volume":"155","author":"Martins","year":"2009","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.jcmg.2018.11.039_bib65","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1016\/j.jacc.2011.06.011","volume":"58","author":"Gersh","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcmg.2018.11.039_bib66","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcmg.2018.11.039_bib67","doi-asserted-by":"crossref","unstructured":"Kovacevic-Preradovic T, Zuber M, Attenhofer Jost CH, et\u00a0al. Anderson-Fabry disease: long-term echocardiographic follow-up under enzyme replacement therapy. Eur J Echocardiogr 2008;9:729\u201335.","DOI":"10.1093\/ejechocard\/jen129"},{"key":"10.1016\/j.jcmg.2018.11.039_bib68","doi-asserted-by":"crossref","unstructured":"Germain DP, Charrow J, Desnick RJ, et\u00a0al. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet 2015;52:353\u20138.","DOI":"10.1136\/jmedgenet-2014-102797"},{"key":"10.1016\/j.jcmg.2018.11.039_bib69","doi-asserted-by":"crossref","unstructured":"Rombach SM, Smid BE, Bouwman MG, Linthorst GE, Dijkgraaf MG, Hollak CE. Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Orphanet J Rare Dis 2013;8:47.","DOI":"10.1186\/1750-1172-8-47"},{"key":"10.1016\/j.jcmg.2018.11.039_bib70","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-000879","article-title":"Effects of enzyme replacement therapy in adult patients with Fabry disease on cardiac structure and function: a retrospective cohort study of the Fabry Munster study (FaMuS) data","volume":"2","author":"Engelen","year":"2012","journal-title":"BMJ Open"},{"key":"10.1016\/j.jcmg.2018.11.039_bib71","doi-asserted-by":"crossref","unstructured":"Madsen CV, Bundgaard H, Rasmussen AK, et\u00a0al. Echocardiographic and clinical findings in patients with Fabry disease during long-term enzyme replacement therapy: a nationwide Danish cohort study. Scand Cardiovasc J 2017;51:207\u201316.","DOI":"10.1080\/14017431.2017.1332383"},{"key":"10.1016\/j.jcmg.2018.11.039_bib72","doi-asserted-by":"crossref","unstructured":"Kim JH, Lee BH, Hyang Cho J, et\u00a0al. Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes. J Hum Genet 2016;61:923\u20139.","DOI":"10.1038\/jhg.2016.78"},{"key":"10.1016\/j.jcmg.2018.11.039_bib73","doi-asserted-by":"crossref","unstructured":"Beck M, Hughes D, Kampmann C, et\u00a0al. Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: a Fabry outcome survey analysis. Mol Genet Metab Rep 2015;3:21\u20137.","DOI":"10.1016\/j.ymgmr.2015.02.002"},{"key":"10.1016\/j.jcmg.2018.11.039_bib74","doi-asserted-by":"crossref","unstructured":"Chen KH, Chien Y, Wang KL, et\u00a0al. Evaluation of proinflammatory prognostic biomarkers for Fabry cardiomyopathy with enzyme replacement therapy. Can J Cardiol 2016;32:1221.e1\u20131221.e9.","DOI":"10.1016\/j.cjca.2015.10.033"},{"key":"10.1016\/j.jcmg.2018.11.039_bib75","doi-asserted-by":"crossref","unstructured":"Chen KH, Chou YC, Hsiao CY, et\u00a0al. Amelioration of serum 8-OHdG level by enzyme replacement therapy in patients with Fabry cardiomyopathy. Biochem Biophys Res Commun 2017;486:293\u2013299.","DOI":"10.1016\/j.bbrc.2017.03.030"},{"key":"10.1016\/j.jcmg.2018.11.039_bib76","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13023-015-0338-2","article-title":"Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment","volume":"10","author":"Kampmann","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jcmg.2018.11.039_bib77","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/j.clinthera.2009.09.008","article-title":"Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis","volume":"31","author":"Kampmann","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.jcmg.2018.11.039_bib78","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/S0140-6736(09)61493-8","article-title":"Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data","volume":"374","author":"Mehta","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jcmg.2018.11.039_bib79","doi-asserted-by":"crossref","unstructured":"Motwani M, Banypersad S, Woolfson P, Waldek S. Enzyme replacement therapy improves cardiac features and severity of Fabry disease. Mol Genet Metab 2012;107:197\u2013202.","DOI":"10.1016\/j.ymgme.2012.05.011"},{"key":"10.1016\/j.jcmg.2018.11.039_bib80","doi-asserted-by":"crossref","unstructured":"Rombach SM, Smid BE, Linthorst GE, Dijkgraaf MG, Hollak CE. Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages. J Inherit Metab Dis 2014;37:341\u201352.","DOI":"10.1007\/s10545-014-9677-8"},{"key":"10.1016\/j.jcmg.2018.11.039_bib81","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003146","article-title":"Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A)","volume":"3","author":"Lin","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.jcmg.2018.11.039_bib82","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1399-0004.2004.00284.x","article-title":"Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease","volume":"66","author":"Spinelli","year":"2004","journal-title":"Clin Genet"},{"key":"10.1016\/j.jcmg.2018.11.039_bib83","doi-asserted-by":"crossref","unstructured":"Kramer J, Bijnens B, Stork S, et\u00a0al. Left ventricular geometry and blood pressure as predictors of adverse progression of Fabry cardiomyopathy. PLoS One 2015;10:e0140627.","DOI":"10.1371\/journal.pone.0140627"},{"key":"10.1016\/j.jcmg.2018.11.039_bib84","doi-asserted-by":"crossref","unstructured":"Arends M, Biegstraaten M, Hughes DA, et\u00a0al. Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: analysis of prognostic factors. PLoS One 2017;12:e0182379.","DOI":"10.1371\/journal.pone.0182379"},{"key":"10.1016\/j.jcmg.2018.11.039_bib85","doi-asserted-by":"crossref","unstructured":"Koeppe S, Neubauer H, Breunig F, et\u00a0al. MR-based analysis of regional cardiac function in relation to cellular integrity in Fabry disease. Int J Cardiol 2012;160:53\u20138.","DOI":"10.1016\/j.ijcard.2011.03.023"},{"key":"10.1016\/j.jcmg.2018.11.039_bib86","doi-asserted-by":"crossref","unstructured":"Weidemann F, Niemann M, Breunig F, et\u00a0al. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 2009;119:524\u20139.","DOI":"10.1161\/CIRCULATIONAHA.108.794529"},{"key":"10.1016\/j.jcmg.2018.11.039_bib87","doi-asserted-by":"crossref","unstructured":"Beer M, Weidemann F, Breunig F, et\u00a0al. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in\u00a0Fabry's cardiomyopathy. Am J Cardiol 2006;97:1515\u20138.","DOI":"10.1016\/j.amjcard.2005.11.087"},{"key":"10.1016\/j.jcmg.2018.11.039_bib88","doi-asserted-by":"crossref","unstructured":"Hughes DA, Elliott PM, Shah J, et\u00a0al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 2008;94:153\u20138.","DOI":"10.1136\/hrt.2006.104026"},{"key":"10.1016\/j.jcmg.2018.11.039_bib89","doi-asserted-by":"crossref","unstructured":"Kramer J, Niemann M, Stork S, et\u00a0al. Relation of burden of myocardial fibrosis to malignant ventricular arrhythmias and outcomes in Fabry disease. Am J Cardiol 2014;114:895\u2013900.","DOI":"10.1016\/j.amjcard.2014.06.019"},{"key":"10.1016\/j.jcmg.2018.11.039_bib90","doi-asserted-by":"crossref","unstructured":"Koskenvuo JW, Hartiala JJ, Nuutila P, et\u00a0al. Twenty-four-month alpha-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters. J Inherit Metab Dis 2008;31:432\u201341.","DOI":"10.1007\/s10545-008-0848-3"},{"key":"10.1016\/j.jcmg.2018.11.039_bib91","doi-asserted-by":"crossref","unstructured":"Imbriaco M, Pisani A, Spinelli L, et\u00a0al. Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study. Heart 2009;95:1103\u20137.","DOI":"10.1136\/hrt.2008.162800"},{"key":"10.1016\/j.jcmg.2018.11.039_bib92","doi-asserted-by":"crossref","unstructured":"Messalli G, Imbriaco M, Avitabile G, et\u00a0al. Role of cardiac MRI in evaluating patients with Anderson-Fabry disease: assessing cardiac effects of long-term enzyme replacement therapy. Radiol Med 2012;117:19\u201328.","DOI":"10.1007\/s11547-011-0710-9"},{"key":"10.1016\/j.jcmg.2018.11.039_bib93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.jcmg.2018.11.039_bib94","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"29","author":"Nagueh","year":"2016","journal-title":"J\u00a0Am Soc Echocardiogr"}],"updated-by":[{"DOI":"10.1016\/j.jcmg.2019.07.004","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000}}],"container-title":["JACC: Cardiovascular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936878X19304619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936878X19304619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T13:29:09Z","timestamp":1721482149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936878X19304619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":94,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S1936878X19304619"],"URL":"https:\/\/doi.org\/10.1016\/j.jcmg.2018.11.039","relation":{},"ISSN":["1936-878X"],"issn-type":[{"value":"1936-878X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of Cardiac Imaging in the Diagnosis and Management of Anderson-Fabry Disease","name":"articletitle","label":"Article Title"},{"value":"JACC: Cardiovascular Imaging","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcmg.2018.11.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2019 Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}